41927-01-9

Usage

Uses

Used in Hair Coloring Industry:
3,4-Dimethyl-o-phenylenediamine is used as a raw material in the production of hair dyes and other hair coloring products for its ability to easily penetrate the hair shaft and produce long-lasting color. However, due to its potential health risks, there are regulations and guidelines in place to ensure its safe use and appropriate concentration in these products.

InChI:InChI=1/C8H12N2/c1-5-3-4-7(9)8(10)6(5)2/h3-4H,9-10H2,1-2H3

Upstream product

• 64823-23-0 3,4-Dimethyl-2-nitroanilin 
• 134-98-5 N-(2,3-dimethylphenyl)acetamide 
• 59146-96-2 2,3-dimethyl-6-nitroaniline 

Downstream Products

• 62192-75-0 2,4,5-trimethyl-1H-benzimidazole 
• 69950-80-7 C₁₈H₃₂N₄O₆P₂S₂ 
• 133626-83-2 11-Ethyl-6,7,8-trimethyl-6,11-dihydro-benzo[b]pyrido[2,3-e][1,4]diazepin-5-one 
• 945389-15-1 C₂₂H₂₉N₃O₂ 
• 115798-89-5 5,6-dimethyl-quinoxaline-1-oxide 
• 890656-23-2 4,5-di methyl-1H-benzimidazole-2-carbaldehyde 
• 208403-94-5 5,6-Dimethyl-1,4-dihydro-quinoxaline-2,3-dione 
• 1093231-04-9 2-chloro-4,5-dimethyl-1H-benzimidazole 
• 1453097-18-1 1-(4,5-dimethyl-1H-benzimidazol-2-yl)-3-methyl-4-(phenylmethyl)-1H-pyrazol-5-ol 
• 1217032-15-9 4,5-dimethyl-1,3-dihydrobenzimidazol-2-one 
• 60986-33-6 C₁₅H₁₄N₂ 
• 35899-34-4 4,5-dimethyl-1H-benzo[d][1,2,3]triazole 

Relevant academic research and scientific papers

Catalytic Reduction of Nitroarenes by Dipalladium Complexes: Synergistic Effect

The direct reaction between 2,7-bis(2-pyridinyl)-1,8-naphthyridine (bpnp) and Pd(CH3COO)2 in CF3COOH yields the new dinuclear palladium(II) complex [Pd2(bpnp)(μ-OH)(CF3CO2)2](CF3CO2) (1). Similarly, substitution of Pd(CH3CN)4(BF4)2 with bpnp in DMF gives [Pd2(bpnp)(μ-OH)(DMF)2](BF4)3 (2). Treatment of 1 or 2 with Cl- readily provide the chloro-substituted species [Pd(bpnp)(μ-OH)(Cl)2]+. All complexes were characterized by spectroscopic methods, and the structure of 2 was further confirmed by X-ray crystallography. Complex 1 is an efficient catalyst for the reduction of aromatic nitro compounds leading to the corresponding aniline derivatives under atmospheric pressure of hydrogen at 50 °C. The mechanistic pathway of the catalysis is investigated. From the reaction pathway, it is suggested that a facile condensation of nitroso and hydroxylamine intermediates is enabled by the dipalladium system and the desired transformation proceeds smoothly under mild reaction conditions to yield the reduced product.

Iridium catalyst complexes and C—H bond activated products therefrom

Provided is a novel iridium catalyst complex which is useful in the dehydrogenation of alkanes. The iridium complex comprises the metal iridium atom complexed with a benzimidazolyl-containing ligand. The iridium atom can be coordinated with the nitrogen a

Process for Alkane Oligomerization

Provided is a process for preparing oligomers from an alkane. The process comprises (a) contacting an alkane under dehydrogenation conditions in the presence of a dehydrogenation catalyst such as an iridium catalyst complex comprising iridium complexed with a benzimidiazolyl-containing ligand to form olefins, and (b) contacting the olefins prepared in step (a) under oligomerization conditions with an oligomerization catalyst such as a nickel, platinum or palladium metal catalyst complex comprising the metal complexed with a nitrogen containing bi- or tridentate ligand to prepare oligomers of the olefins, and hydrogenating the olefin oligomers. In one embodiment, the ligands of the catalyst complexes in step (a) and step (b) can be the same.

Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer''s, Parkinson''s, and Huntington''s Diseases.